Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 15/20 | 0.69 |
| ▸ | CCR6 | P51684 | 9/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 8/20 | 0.49 |
| ▸ | CCR7 | P32248 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.48 |
| ▸ | CCR4 | P51679 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17871622 | 1.00 | CXCR2 (0.69) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL19678021 | 0.89 | CXCR2 (0.69) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL19678014 | 0.87 | CXCR2 (0.71) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL19678013 | 0.84 | CXCR2 (0.73) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL12262979 | 0.83 | CXCR2 (0.75) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL12205558 | 0.82 | CXCR2 (0.74) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL19678015 | 0.82 | CXCR2 (0.64) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL1579021 | 0.82 | CXCR2 (1.00) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL20452238 | 0.82 | CXCR2 (1.00) | CXCR2CCR6CXCR1CCR7CXCR3 | |
| SCHEMBL30515707 | 0.82 | CXCR2 (1.00) | CXCR2CCR6CXCR1CCR7CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647706-B2 | Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | claimed |
| US-20190225598-A1 | NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-07-25 | — | — | US | claimed |
| US-10287278-B2 | Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-05-14 | — | — | US | claimed |
| EP-3237384-B1 | NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | claimed |
| US-20170349575-A1 | NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-12-07 | — | — | US | claimed |
| US-10647706-B2 | Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | disclosed |
| US-20190225598-A1 | NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-07-25 | — | — | US | disclosed |
| US-10287278-B2 | Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-05-14 | — | — | US | disclosed |
| EP-3237384-B1 | NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | disclosed |
| US-20170349575-A1 | NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287278-B2 | Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies | CXCR1, CXCR2, CXCR3 | CXCR2 2/4885CCR6 19/4885CXCR1 1/4885 |
| US-10647706-B2 | Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies | CXCR1, CXCR2, CXCR3 | CXCR2 2/4885CCR6 19/4885CXCR1 1/4885 |
| US-20170349575-A1 | NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CCR6 20/4885CXCR1 2/4885 |
| US-20190225598-A1 | NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CCR6 20/4885CXCR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.